Durability of Antiviral Response in HBeAg-Positive Chronic Hepatitis B Patients Who Maintained Virologic Response for One Year After Lamivudine Discontinuation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Lee, Sun Jae | - |
dc.contributor.author | Joo, Moon Kyung | - |
dc.contributor.author | Kim, Chung Ho | - |
dc.contributor.author | Choi, Jong Hwan | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Park, Jong-Jae | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Bak, Young Tae | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.available | 2020-11-03T08:43:39Z | - |
dc.date.issued | 2009-07 | - |
dc.identifier.issn | 0163-2116 | - |
dc.identifier.issn | 1573-2568 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/15927 | - |
dc.description.abstract | The purpose of this study is to determine the long-term relapse rate and associated risk factors in HBeAg-positive chronic hepatitis B (CHB) patients who had maintained virologic response (VR) for 1 year after lamivudine (LMV) discontinuation. We enrolled 55 treatment-naive HBeAg-positive CHB patients who achieved and maintained VR until 1 year after LMV discontinuation. Delayed relapse was defined as an elevation of HBV DNA after sustained VR for 1 year. During follow-up, 16 of 55 patients (29%) showed delayed relapse. Beginning 1 year after LMV discontinuation, the cumulative rates of relapse after 2 and 4 years were 29 and 44%, respectively. In multivariate analysis, age (P = 0.029) and > 2,000 copies/ml HBV DNA 3 months after LMV discontinuation (P = 0.047) were significant predictors of delayed relapse. Delayed relapse is not infrequent, even in patients who maintain VR for 1 year after LMV discontinuation. Therefore, LMV maintenance therapy might be considered in HBeAg-positive CHB patients who achieve VR. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Kluwer Academic/Plenum Publishers | - |
dc.title | Durability of Antiviral Response in HBeAg-Positive Chronic Hepatitis B Patients Who Maintained Virologic Response for One Year After Lamivudine Discontinuation | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1007/s10620-008-0508-3 | - |
dc.identifier.scopusid | 2-s2.0-67349181363 | - |
dc.identifier.wosid | 000266654900028 | - |
dc.identifier.bibliographicCitation | Digestive Diseases and Sciences, v.54, no.7, pp 1572 - 1577 | - |
dc.citation.title | Digestive Diseases and Sciences | - |
dc.citation.volume | 54 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1572 | - |
dc.citation.endPage | 1577 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | YMDD MOTIF | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | SEROCONVERSION | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordPlus | GENOTYPE | - |
dc.subject.keywordPlus | RELAPSE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Lamivudine | - |
dc.subject.keywordAuthor | Response | - |
dc.subject.keywordAuthor | Relapse | - |
dc.subject.keywordAuthor | Durability | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.